Ensysce Biosciences, Inc. (NASDAQ:ENSC – Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 84,700 shares, a growth of 85.7% from the December 15th total of 45,600 shares. Based on an average daily volume of 1,800,000 shares, the short-interest ratio is currently 0.0 days.
Institutional Trading of Ensysce Biosciences
An institutional investor recently bought a new stake in Ensysce Biosciences stock. Anson Funds Management LP acquired a new stake in shares of Ensysce Biosciences, Inc. (NASDAQ:ENSC – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 983,518 shares of the company’s stock, valued at approximately $236,000. Anson Funds Management LP owned about 11.15% of Ensysce Biosciences as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.63% of the company’s stock.
Ensysce Biosciences Price Performance
Shares of ENSC stock traded down $0.42 on Tuesday, hitting $6.75. 52,040 shares of the stock traded hands, compared to its average volume of 58,199. Ensysce Biosciences has a 52 week low of $2.12 and a 52 week high of $30.90. The firm has a 50 day simple moving average of $8.28 and a two-hundred day simple moving average of $6.61. The firm has a market cap of $8.82 million, a price-to-earnings ratio of -0.25 and a beta of 0.55.
Ensysce Biosciences Company Profile
Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Read More
- Five stocks we like better than Ensysce Biosciences
- Market Cap Calculator: How to Calculate Market Cap
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- What is a Special Dividend?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.